You are now leaving www.amvuttrahcp.com.
You are now being directed to another Alnylam website.
Proceed CancelHow to administer AMVUTTRA
(See section 2.2 of full Prescribing Information for complete Administration Instructions.)
Missing a dose
*Based on patients enrolled in Alnylam Assist® January 2024 to July 2026.3
No head-to-head trials have been conducted. Conclusions about similarities and/or differences in clinical profiles cannot be drawn.
ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis; HCP=healthcare professional.
Reduced Serum Vitamin A Levels and Recommended Supplementation
AMVUTTRA treatment leads to a decrease in serum vitamin A levels.
Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).
Adverse Reactions
In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).
In a study of patients with ATTR-CM, no new safety issues were identified.
AMVUTTRA® (vutrisiran) is indicated for the treatment of the:
For additional information about AMVUTTRA, please see the full Prescribing Information .
IMPORTANT SAFETY INFORMATION AND INDICATIONS